DE3751092T2 - Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems. - Google Patents

Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems.

Info

Publication number
DE3751092T2
DE3751092T2 DE3751092T DE3751092T DE3751092T2 DE 3751092 T2 DE3751092 T2 DE 3751092T2 DE 3751092 T DE3751092 T DE 3751092T DE 3751092 T DE3751092 T DE 3751092T DE 3751092 T2 DE3751092 T2 DE 3751092T2
Authority
DE
Germany
Prior art keywords
immunogenicity
production
expression system
baculovirus expression
rotavirus genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3751092T
Other languages
English (en)
Other versions
DE3751092D1 (de
Inventor
Mary K Estes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Application granted granted Critical
Publication of DE3751092D1 publication Critical patent/DE3751092D1/de
Publication of DE3751092T2 publication Critical patent/DE3751092T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
DE3751092T 1986-12-30 1987-12-22 Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems. Expired - Fee Related DE3751092T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/947,773 US5186933A (en) 1986-12-30 1986-12-30 Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system

Publications (2)

Publication Number Publication Date
DE3751092D1 DE3751092D1 (de) 1995-03-30
DE3751092T2 true DE3751092T2 (de) 1995-06-14

Family

ID=25486741

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3751092T Expired - Fee Related DE3751092T2 (de) 1986-12-30 1987-12-22 Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems.

Country Status (6)

Country Link
US (4) US5186933A (de)
EP (1) EP0273366B1 (de)
JP (1) JPS63273478A (de)
AU (1) AU618521B2 (de)
CA (1) CA1339732C (de)
DE (1) DE3751092T2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
CA1319101C (en) * 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
EP0402354A4 (en) * 1987-08-10 1991-03-20 The University Of Melbourne Molecular cloning of human rotavirus serotype 4 gene 9 encoding vp7, the major outer capsid neutralisation specific glycoprotein and expression of vp7 and fragments thereof for use in a vaccine
AU621065B2 (en) * 1987-08-10 1992-03-05 University Of Melbourne, The Molecular cloning of human rotavirus serotype 4 gene 9 encoding vp7, the major outer capsid neutralisation specific glycoprotein and expression of vp7 and fragments thereof for use in a vaccine
GB9000143D0 (en) * 1990-01-04 1990-03-07 Natural Environment Res Test kit and method for the diagnosis of bluetongue
US5298244A (en) * 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
US5431899A (en) * 1991-02-04 1995-07-11 University Of Saskatchewan Rotavirus VP6 as a diagnostic and targeting agent
PT100090A (pt) * 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
DE69213030D1 (de) * 1991-02-04 1996-09-26 Univ Saskatchewan Arzneistoffabgabe aus VP6-Kapseln
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US6165993A (en) * 1992-03-23 2000-12-26 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
CA2144651A1 (en) * 1992-09-14 1994-03-31 Timothy J. Miller Immortalized cells and uses therefor
WO1995017515A1 (en) 1993-12-23 1995-06-29 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
EP0833670B1 (de) 1995-06-14 2003-09-03 Baylor College Of Medicine impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
US6270795B1 (en) * 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
EP1054990A2 (de) * 1998-02-12 2000-11-29 Aventis Research & Technologies GmbH & Co KG Expressionsvektor zur herstellung von dead-proteinen
EP1349571A4 (de) * 2000-11-03 2005-02-16 Baylor College Medicine Rotavirus-enterotoxin nsp4 und verfahren zu seiner verwendung
KR20030026654A (ko) * 2001-09-26 2003-04-03 주식회사 씨트리 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용
AU2003213167A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Sequence analysis of the tetravalent rotavirus vaccine
US20060165657A1 (en) * 2003-02-05 2006-07-27 Paul Bernasconi Method for delivery of cosmetic by topical application
WO2005074524A2 (en) * 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
AU2005319099B2 (en) * 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
EP1771573A4 (de) * 2004-07-21 2009-02-18 Ambrx Inc Nichtnatürliche kodierte aminosäuren verwendende biosynthetische polypeptide
JP4990792B2 (ja) * 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド アミノアシル−ｔＲＮＡシンテターゼの組成物およびこの使用
MX2007007587A (es) 2004-12-22 2007-12-11 Ambrx Inc Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
CN103290084A (zh) 2004-12-22 2013-09-11 Ambrx公司 表达和纯化重组人类生长激素的方法
EP1828224B1 (de) 2004-12-22 2016-04-06 Ambrx, Inc. Zusammensetzungen mit, verfahren mit und verwendungen von nichtnatürlichen aminosäuren und polypeptiden
JP2008541769A (ja) * 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド 改善されたヒトインターフェロン分子及びそれらの使用
MX2008002149A (es) 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
BRPI0504441A (pt) * 2005-10-20 2007-06-26 Fundacao Oswaldo Cruz vetores de expressão plasmidial contendo regiões especìficas para a expressão de proteìnas ou epìtopos recombinantes de rotavìrus e astrovìrus, processo de produção dos insumos para geração de imunobiológicos para diagnóstico
RS51998B (en) * 2005-11-08 2012-04-30 Ambrx Inc. ACCELERATORS FOR MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES
CA2626522A1 (en) * 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
SG170116A1 (en) * 2005-12-14 2011-04-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CN101511856B (zh) * 2006-09-08 2016-01-20 Ambrx公司 脊椎动物细胞中抑制因子trna的转录
JP5399906B2 (ja) * 2006-09-08 2014-01-29 アンブルックス，インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
CN106008699A (zh) * 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
NZ620606A (en) 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses
PE20110426A1 (es) 2008-07-23 2011-07-01 Ambrx Inc Polipeptidos g-csf bovinos modificados
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
CN102224238B (zh) 2008-09-26 2015-06-10 Ambrx公司 非天然氨基酸复制依赖性微生物和疫苗
CA2784800A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
WO2011136506A2 (ko) * 2010-04-30 2011-11-03 중앙대학교 산학협력단 로타바이러스 나노입자를 이용한 재조합 복합 항원의 제조방법
RS59193B1 (sr) 2010-08-17 2019-10-31 Ambrx Inc Modifikovani polipeptidi relaksina i njihova primena
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CN104203274B (zh) 2012-02-14 2017-09-08 梅里亚股份有限公司 轮状病毒亚单位疫苗及其制备和使用的方法
PT3412302T (pt) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Polipéptidos de fgf-21 modificados e utilizações dos mesmos
CN110637027A (zh) 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
CN115551530A (zh) 2019-08-27 2022-12-30 通尼克斯制药有限公司 经修饰的tff2多肽

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339735C (en) * 1984-04-27 1998-03-17 Ian Hamilton Holmes. Cloning and sequencing of the major outer capsid gylcoprotein gene of a human rotavirus
AU579242B2 (en) * 1985-05-23 1988-11-17 Comalco Aluminium Limited Bauxite proppant
US4853333A (en) * 1985-07-26 1989-08-01 American Home Products Corporation Production of rotavirus in yeast
EP0251467A3 (de) * 1986-06-20 1988-07-20 Abbott Laboratories Zusammensetzungen und Verfahren zum Gebrauch eines Haupt-Aussen-Kapsid-Proteins (VP7) des Rotavirus SA-11
US4861845A (en) * 1988-03-10 1989-08-29 E. I. Du Pont De Nemours And Company Polymerization of fluoroolefins

Also Published As

Publication number Publication date
EP0273366A1 (de) 1988-07-06
EP0273366B1 (de) 1995-02-22
AU618521B2 (en) 1992-01-02
JPS63273478A (ja) 1988-11-10
US5827696A (en) 1998-10-27
US5843733A (en) 1998-12-01
CA1339732C (en) 1998-03-17
US5891676A (en) 1999-04-06
AU8310887A (en) 1988-06-30
DE3751092D1 (de) 1995-03-30
US5186933A (en) 1993-02-16

Similar Documents

Publication Publication Date Title
DE3751092D1 (de) Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems.
DE3789399D1 (de) Herstellung von Vakkzinen gegen Hepatitis B-Virus.
DE3785389D1 (de) Herstellung eines kabels.
DE3780933D1 (de) Herstellung von aminoalanen.
DE68919986D1 (de) Herstellung eines Katheters.
DE3650339D1 (de) Herstellung von Urandioxid-Material.
DE3786091T2 (de) Herstellung tomographischer abbildungen.
DE3785132T2 (de) Herstellung optisch aktiver cyclopropancarbonsäuren.
DE3688937T2 (de) Herstellung optisch aktiver aryloxypropanolamine und arylaethanolamine.
DE3780179T2 (de) Herstellung von menschlichem erythropoietin.
DE3789316T2 (de) Herstellung von human-parathyroidhormon.
DE3778134D1 (de) Kontinuierliche herstellung von dialkansulfonylperoxiden.
DE68921340D1 (de) Herstellung von epoxinitraten.
DE3787499D1 (de) Herstellung eines Plasminogenaktivators.
DE68907733D1 (de) Herstellung von duesen.
DE3765326D1 (de) Herstellung eines gummischaumes.
DE343495T1 (de) Herstellung von alkylsilanen.
DE68905638D1 (de) Herstellung von alkansulfonylhaliden und alkansulfonsaeuren.
DE3582180D1 (de) Lebender attenuierter menschlicher rotavirus-impfstoff und herstellung desselben.
DE69007152D1 (de) Herstellung eines Difluorhalogenmethoxybenzols.
DE3777709D1 (de) Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis.
DE68906449T2 (de) Herstellung von 2,6-dioxopiperidinderivate.
DE3880110T2 (de) Herstellung von m-aminophenol.
DE3773219D1 (de) Herstellung von tetrachlorpyridin.
DE3783599D1 (de) Biologische regulierung der dehydratisierung und des verfaulens von wurzeln und herstellung einer impfung dafuer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee